Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Assessment of Islet Alpha- and Beta-Cell Function

    Research output: Chapter in Book/Report/Conference proceedingBook chapterCommunication

  • Simon Birk Kjær Jensen
  • Julie Rehné Lundgren
  • Charlotte Janus
  • Christian Rimer Juhl
  • Lisa Møller Olsen
  • Mads Rosenkilde
  • Jens Juul Holst
  • Bente Merete Stallknecht
  • Sten Madsbad
  • Signe Sørensen Torekov
View graph of relations

INTRODUCTION: The success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss followed by 1-year treatment with a glucagon-like peptide-1 receptor agonist (liraglutide), physical exercise or the combination of both treatments as compared with placebo in individuals with obesity.

METHODS AND ANALYSIS: This is an investigator-initiated, randomised, placebo-controlled, parallel group trial. We will enrol expectedly 200 women and men (age 18-65 years) with obesity (body mass index 32-43 kg/m2) to adhere to a very low-calorie diet (800 kcal/day) for 8 weeks in order to lose at least 5% of body weight. Subsequently, participants will be randomised in a 1:1:1:1 ratio to one of four study groups for 52 weeks: (1) placebo, (2) exercise 150 min/week+placebo, (3) liraglutide 3.0 mg/day and (4) exercise 150 min/week+liraglutide 3.0 mg/day. The primary endpoint is change in body weight from randomisation to end-of-treatment.

ETHICS AND DISSEMINATION: The trial has been approved by the ethical committee of the Capital Region of Denmark and the Danish Medicines Agency. The trial will be conducted in agreement with the Declaration of Helsinki and monitored to follow the guidelines for good clinical practice. Results will be submitted for publication in international peer-reviewed scientific journals.


Original languageEnglish
Article numbere031431
JournalBMJ Open
Issue number11
Pages (from-to)e031431
Publication statusPublished - 2 Nov 2019

    Research areas

  • exercise, GLP-1 receptor agonist, liraglutide, obesity, weight loss, weight loss maintenance

ID: 58289840